Veradermics Raises Funding with 3.35M-Share Offering and Reports Positive Phase 2/3 Results
Veradermics launched a public offering of 3.35 million common shares and pre-funded warrants, with a 30-day option for 502,500 additional shares and a private placement to Suvretta Capital affiliates. The company reported positive topline results from its Phase 2/3 VDPHL01 trial, advancing its oral non-hormonal minoxidil formulation for mild-to-moderate hair loss.
1. Public Offering Launch
Veradermics announced a proposed public offering of 3.35 million common shares and pre-funded warrants, granting underwriters a 30-day option to purchase an additional 502,500 shares. Concurrently, it plans a private placement of an equal number of pre-funded warrants with affiliates of Suvretta Capital, subject to market conditions.
2. Phase 2/3 Trial Topline
The company disclosed positive topline results from its Phase 2/3 study of VDPHL01, its oral non-hormonal minoxidil formulation for treating mild-to-moderate pattern hair loss. These findings support advancement of VDPHL01 toward later-stage development and potential regulatory filings.